More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Up to 30% of patients have metastatic disease by the time they are initially diagnosed with renal cell carcinoma, making accurate staging a critical element of treatment planning.
Experts have identified numerous white matter features, in addition to changes in white matter tracts that occur over time, which they believe are more common among people with ADHD.
In individuals who have not completed a DEXA scan, head CT conducted for other reasons can offer insight into patients’ frontal bone density, a potential marker of osteoporosis.
